News
David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in ...
Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I ...
While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the ...
Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound. Shares ...
Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Composite were up modestly.
Shares of Scholar Rock (NASDAQ: SRRK) shot 364% higher on Monday, Oct. 7, 2024. The market was reacting to surprisingly positive news regarding the clinical-stage drugmaker's lead candidate ...
Scholar Rock said regulatory submissions for apitegromab in the U.S. and Europe are planned for the first quarter of next year, setting the stage for a potential fourth quarter 2025 commercial launch.
Scholar Rock's C-suite now looks radically different, as the company brought in a clutch of new top managers. The incoming CEO is David Hallal, the chairman of the company's board.
Scholar Rock Holding Corp.'s stock soared more than 315% Monday to put it on track for its biggest ever one-day gain, after the clinical-stage biotech company said a late-stage trial of a ...
Review the current valuation for Scholar Rock Holding Corp (SRRK:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.
Scholar Rock's C-suite now looks radically different, as the company brought in a clutch of new top managers. The incoming CEO is David Hallal, the chairman of the company's board.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results